



30th April, 2018

Appointment of a Director

The Board of SomnoMed is pleased to announce the appointment of Mr Hamish Corlett as a Director of the Company, effective 1st May 2018.

Hamish is a founder and director of TDM Asset Management Pty Limited, a leading private investment firm specializing in long term investments in high growth companies globally. TDM made its first investment in SomnoMed in April 2010 and has been a substantial shareholder in the Company since October 2012.

Prior to TDM, Hamish worked as an Investment Manager at Caledonia Investments, a global fund manager. He has extensive investment experience in North America and worked for a number of years in London in an operating role at Europe's largest online retailer of sporting goods. After returning to Sydney, he worked in mergers and acquisition corporate advisory with Caliburn Partnership (now Greenhill).

Hamish holds a Bachelor of Commerce with Honours Class 1 (Accounting and Finance) from the University of Sydney and a Graduate Diploma of Counselling from the Australian College of Applied Psychologists.

"We are delighted to welcome Hamish to the Board of SomnoMed. Hamish's personal track record, his experience in finance and international business operations, and the enormous success he and his colleagues in TDM have achieved over a period of more than a decade in identifying and partnering with outstanding growth businesses, will make him a most valuable addition to our board," commented SomnoMed's Chairman Dr Peter Neustadt.

Mr Corlett said, "I have followed SomnoMed's development for more than ten years. TDM is a significant, long term shareholder in the business and we are very excited by the large, global growth opportunity ahead. I am very much looking forward to the opportunity to work closely with the Board and management of SomnoMed."

Mr Corlett will resign from the Board and stand for election to the Board at the company's AGM to be held in November.

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent[®] is the most comfortable and effective design and treatment solution for over 400,000 patients in 28 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>